Abstract:Introduction The intricate interplay of interleukin-10 (IL-10) and gut microbiota influences tumor development and progression, yet the impacts on colorectal cancer (CRC) metastasis remain incompletely understood. Methods The impact of Il10 deficiency on CRC metastasis was first evaluated in CRC metastasis tumor samples and mouse model. Antibiotic sterilization and fecal microbiota transplantation (FMT) experiment were used to assess the role of gut microbiota in IL-10 mediated CRC metastasis, and full-length 16S rDNA sequencing analysis further identified the potential target bacteria influencing CRC metastasis. The inhibitory effect of Parabacteroides distasonis (P. distasonis) on CRC metastasis was evaluated by oral administration in mice. Key metabolites involved in P. distasonis inhibition of CRC metastasis was identified by widely-targeted metabolome analysis and validated both in vivo and in vitro. The underlying mechanisms of P-hydroxyphenyl acetic acid (4-HPAA) inhibiting CRC metastasis was investigated via RNA-sequencing and validated in cellular experiments. Results We revealed that serum IL-10 levels were markedly elevated in metastatic CRC patients compared to non-metastatic cases. In parallel, Il10-deficiency (Il10−/) in mice resulted in decreased CRC metastasis in a gut microbiota-dependent manner. Mechanistically, Il10−/− mice reshaped gut microbiota composition, notably enriching P. distasonis. The enriched P. distasonis produced 4-HPAA, which activated the aryl hydrocarbon receptor (AHR) and subsequently inhibited the expression of VEGFA, a typical oncogene, thereby sequentially suppressing CRC metastasis. Importantly, engineered bacteria capable of producing 4-HPAA effectively hindered CRC metastasis. Furthermore, AHR depletion significantly disrupted the 4-HPAA-induced reduction in CRC cell migration and the inhibition of metastasis in both in vitro and in vivo lung metastasis mouse models. Conclusions These findings demonstrate the significance of IL-10 deficiency in suppressing CRC metastasis through the 4-HPPA-AHR-VEGFA axis mediated by gut P. distasonis, suggesting that P. distasonis or 4-HPAA supplementation could offer a promising therapeutic strategy for CRC metastasis prevention.

Interleukin-12: Structure, Function, and Its Impact in Colorectal Cancer

Interleukin-13 and Its Receptors in Colorectal Cancer (Review)

Antitumor Activities of Interleukin-12 in Melanoma

Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy

Progress of IL-12 in Tumor Immunotherapy

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy

New Insights on IL‑36 in Intestinal Inflammation and Colorectal Cancer (Review)

Interleukin-36α inhibits colorectal cancer metastasis by enhancing the infiltration and activity of CD8+ T lymphocytes

Emerging IL-12-based nanomedicine for cancer therapy

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.

[Progress on Interleukin-27 in Tumor Immunity].

Cmar_a_262745 7527..7537

IL-13 / STAT 6 Signaling Plays a Critical Role in the Epithelial-Mesenchymal Transition of Colorectal Cancer Cells

IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment

Enhanced gut barrier integrity sensitizes colon cancer to immune therapy

Interleukin 12 Shows a Better Curative Effect on Lung Cancer Than Paclitaxel and Cisplatin Doublet Chemotherapy

Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring

Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction

IL12p40 regulates functional development of human CD4+ T cells: enlightenment by the elevated expressions of IL12p40 in patients with inflammatory bowel diseases.

IL‐36 γ and IL‐36Ra Reciprocally Regulate Colon Inflammation and Tumorigenesis by Modulating the Cell–Matrix Adhesion Network and Wnt Signaling

Interleukin-10 Deficiency Suppresses Colorectal Cancer Metastasis by Enriching Gut Parabacteroides Distasonis